Cargando…

An overview of the BOIN design and its current extensions for novel early-phase oncology trials

Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-finding designs that can be used in oncology trials to determine the maximum tolerated dose (MTD) of a study drug based on safety or the optimal biological dose (OBD) based on safety and efficacy. BOIN designs provide a comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ananthakrishnan, Revathi, Lin, Ruitao, He, Chunsheng, Chen, Yanping, Li, Daniel, LaValley, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260438/
https://www.ncbi.nlm.nih.gov/pubmed/35812822
http://dx.doi.org/10.1016/j.conctc.2022.100943
_version_ 1784742029915324416
author Ananthakrishnan, Revathi
Lin, Ruitao
He, Chunsheng
Chen, Yanping
Li, Daniel
LaValley, Michael
author_facet Ananthakrishnan, Revathi
Lin, Ruitao
He, Chunsheng
Chen, Yanping
Li, Daniel
LaValley, Michael
author_sort Ananthakrishnan, Revathi
collection PubMed
description Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-finding designs that can be used in oncology trials to determine the maximum tolerated dose (MTD) of a study drug based on safety or the optimal biological dose (OBD) based on safety and efficacy. BOIN designs provide a complete suite for dose finding in early phase trials, as well as a consistent way to explore different scenarios such as toxicity, efficacy, continuous outcomes, delayed toxicity or efficacy and drug combinations in a unified manner with easy access to software to implement most of these designs. Although built upon Bayesian probability models, BOIN designs are operationally simple in general and have good statistical operating characteristics compared to other dose-finding designs. This review paper describes the original BOIN design and its many extensions, their advantages and limitations, the software used to implement them, and the most suitable situation for use of each of these designs. Published examples of the implementation of BOIN designs are provided in the Appendix.
format Online
Article
Text
id pubmed-9260438
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92604382022-07-08 An overview of the BOIN design and its current extensions for novel early-phase oncology trials Ananthakrishnan, Revathi Lin, Ruitao He, Chunsheng Chen, Yanping Li, Daniel LaValley, Michael Contemp Clin Trials Commun Article Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-finding designs that can be used in oncology trials to determine the maximum tolerated dose (MTD) of a study drug based on safety or the optimal biological dose (OBD) based on safety and efficacy. BOIN designs provide a complete suite for dose finding in early phase trials, as well as a consistent way to explore different scenarios such as toxicity, efficacy, continuous outcomes, delayed toxicity or efficacy and drug combinations in a unified manner with easy access to software to implement most of these designs. Although built upon Bayesian probability models, BOIN designs are operationally simple in general and have good statistical operating characteristics compared to other dose-finding designs. This review paper describes the original BOIN design and its many extensions, their advantages and limitations, the software used to implement them, and the most suitable situation for use of each of these designs. Published examples of the implementation of BOIN designs are provided in the Appendix. Elsevier 2022-06-13 /pmc/articles/PMC9260438/ /pubmed/35812822 http://dx.doi.org/10.1016/j.conctc.2022.100943 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ananthakrishnan, Revathi
Lin, Ruitao
He, Chunsheng
Chen, Yanping
Li, Daniel
LaValley, Michael
An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title_full An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title_fullStr An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title_full_unstemmed An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title_short An overview of the BOIN design and its current extensions for novel early-phase oncology trials
title_sort overview of the boin design and its current extensions for novel early-phase oncology trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260438/
https://www.ncbi.nlm.nih.gov/pubmed/35812822
http://dx.doi.org/10.1016/j.conctc.2022.100943
work_keys_str_mv AT ananthakrishnanrevathi anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT linruitao anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT hechunsheng anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT chenyanping anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT lidaniel anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT lavalleymichael anoverviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT ananthakrishnanrevathi overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT linruitao overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT hechunsheng overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT chenyanping overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT lidaniel overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials
AT lavalleymichael overviewoftheboindesignanditscurrentextensionsfornovelearlyphaseoncologytrials